Purpose. Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components. Owing to its scarcity, data regarding the impact of available treatments on the clinical outcomes of gliosarcoma are inadequate. The purpose of this retrospective cohort study was to analyze the prognostic factors of gliosarcoma. Methods. By screening the clinical database of neurosurgical cases at a single center, patients with gliosarcoma diagnosed histologically from 2013 to 2021 were identified. Clinical, pathological, and molecular data were gathered founded on medical records and follow-up interviews. Prognostic factors were derived using the Cox proportional hazards model with backward stepwise regression analysis. Results. Forty-five GSM patients were included. Median overall survival was 25.6 months (95% CI 8.0–43.1), and median relapse-free survival was 15.2 months (95% CI 9.7–20.8). In multivariable analysis, total resection ( p = 0.023 , HR = 0.192 , 95% CI 0.046–0.797) indicated an improved prognosis. And low expression of Ki-67 ( p = 0.059 , HR = 2.803 , 95% CI 0.963–8.162) would be likely to show statistical significance. However, there might be no statistically significant survival benefit from radiotherapy with concurrent temozolomide ( n = 33 , 73.3%, log-rank p = 0.99 ) or adjuvant temozolomide ( n = 32 , 71.1%, log-rank p = 0.74 ). Conclusion. This single-center retrospective study with a limited cohort size has demonstrated the treatment of gross total resection and low expression of Ki-67 which are beneficial for patients with GSM, while radiotherapy or temozolomide is not.
Introduction: Gliosarcoma is a histopathological variant of glioblastoma, which is characterized by a biphasic growth pattern consisting of glial and sarcoma components. Owing to its scarcity, data regarding the impact of available treatments on the clinical outcomes of gliosarcoma are inadequate. The purpose of this retrospective cohort study was to analyze the prognostic factors of gliosarcoma. Methods By screening the clinical database of neurosurgical cases at a single center, patients with gliosarcoma diagnosed histologically from 2015 to 2021 were identified. Clinical, pathological and molecular data were gathered founded on medical records and follow-up interviews. Prognostic factors were derived using Cox proportional hazards model with backward stepwise regression analysis. Results Forty-five GSM patients were included. Median overall survival was 20.6 months (95%CI 5.8 – 35.3), and median relapse free survival was 15.2 months (95%CI 6.1 – 24.3). In multivariable analysis, total resection (p = 0.029, HR = 0.198, 95%CI 0.046 – 0.849) indicated an improved prognosis. And low expression of Ki-67 (p = 0.067, HR = 2.813, 95%CI 0.930 – 8.506) would be likely to show statistical significance. However, there might be no statistically significant survival benefit from radiotherapy (n = 33, 75%, log-rank p = 0.92), adjuvant temozolomide (n = 33, 73.3%, log-rank p = 0.78) or concurrent temozolomide (n = 36, 80%, log-rank p = 0.79). Conclusion This retrospective study with a limited cohort size has demonstrated the treatment of gross total resection and low expression of Ki-67 are beneficial for patients with GSM, while radiotherapy or temozolomide is not.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.